Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) have been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the company. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $12.43.
Several brokerages have recently commented on ARGS. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Argos Therapeutics in a report on Friday, June 17th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $11.00 target price on shares of Argos Therapeutics in a report on Monday, June 20th. Zacks Investment Research downgraded shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. Finally, FBR & Co reduced their price target on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 11th.
Shares of Argos Therapeutics (NASDAQ:ARGS) opened at 4.61 on Monday. The firm has a 50-day moving average of $4.89 and a 200 day moving average of $5.89. Argos Therapeutics has a 52 week low of $1.61 and a 52 week high of $13.97. The firm’s market cap is $189.91 million.
Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. Equities research analysts predict that Argos Therapeutics will post ($1.56) EPS for the current fiscal year.
In other Argos Therapeutics news, major shareholder International S. Pharmstandard bought 75,474 shares of the business’s stock in a transaction on Monday, August 22nd. The stock was purchased at an average price of $4.24 per share, for a total transaction of $320,009.76. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder International S. Pharmstandard bought 16,977 shares of the business’s stock in a transaction on Thursday, September 1st. The shares were acquired at an average price of $4.78 per share, with a total value of $81,150.06. The disclosure for this purchase can be found here. Company insiders own 61.64% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Oxford Asset Management acquired a new position in shares of Argos Therapeutics during the second quarter worth $353,000. Geode Capital Management LLC raised its position in shares of Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares in the last quarter. California State Teachers Retirement System acquired a new position in shares of Argos Therapeutics during the second quarter worth $137,000. Bank of New York Mellon Corp raised its position in shares of Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 33,862 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Argos Therapeutics during the second quarter worth $137,000. Hedge funds and other institutional investors own 11.05% of the company’s stock.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.